- Home
- RFIL vs CTSO Comparison
RFIL vs CTSO Comparison
Compare RFIL & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFIL
- CTSO
- Stock Information
- Founded
- RFIL 1979
- CTSO 1997
- Country
- RFIL United States
- CTSO United States
- Employees
- RFIL N/A
- CTSO N/A
- Industry
- RFIL Electrical Products
- CTSO Medical/Dental Instruments
- Sector
- RFIL Technology
- CTSO Health Care
- Exchange
- RFIL Nasdaq
- CTSO Nasdaq
- Market Cap
- RFIL 42.4M
- CTSO 48.2M
- IPO Year
- RFIL N/A
- CTSO N/A
- Fundamental
- Price
- RFIL $3.75
- CTSO $0.86
- Analyst Decision
- RFIL Strong Buy
- CTSO Strong Buy
- Analyst Count
- RFIL 1
- CTSO 3
- Target Price
- RFIL $4.50
- CTSO $4.67
- AVG Volume (30 Days)
- RFIL 8.6K
- CTSO 135.6K
- Earning Date
- RFIL 01-21-2025
- CTSO 11-07-2024
- Dividend Yield
- RFIL N/A
- CTSO N/A
- EPS Growth
- RFIL N/A
- CTSO N/A
- EPS
- RFIL N/A
- CTSO N/A
- Revenue
- RFIL $62,278,000.00
- CTSO $37,739,531.00
- Revenue This Year
- RFIL N/A
- CTSO $8.08
- Revenue Next Year
- RFIL $8.38
- CTSO $12.80
- P/E Ratio
- RFIL N/A
- CTSO N/A
- Revenue Growth
- RFIL N/A
- CTSO 1.80
- 52 Week Low
- RFIL $2.61
- CTSO $0.70
- 52 Week High
- RFIL $4.65
- CTSO $1.97
- Technical
- Relative Strength Index (RSI)
- RFIL 34.00
- CTSO 42.77
- Support Level
- RFIL $4.07
- CTSO $0.80
- Resistance Level
- RFIL $4.39
- CTSO $1.09
- Average True Range (ATR)
- RFIL 0.16
- CTSO 0.08
- MACD
- RFIL -0.04
- CTSO -0.00
- Stochastic Oscillator
- RFIL 0.00
- CTSO 13.19
About RFIL RF Industries Ltd.
RF Industries Ltd is engaged in the design, manufacture, and marketing of interconnect products and systems, including coaxial and specialty cables, fiber optic cables and connectors, and electrical and electronic specialty cables. The company operates through two segments: RF Connector and Cable Assembly, which consists of the Connector and Cable Assembly Division, and Custom Cabling Manufacturing and Assembly, which consists of its subsidiaries. The company has operations in the United States, Canada, Israel, and Mexico.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.